Zinfandel New Public Database of Short Structural Variants Helps Researchers Pinpoint ALS Risk Marker Experts led by Duke neuroscientist Allen Roses developed the database hoping to boost researchers' ability to explore the role of short structural variants in complex diseases. Duke Researchers Present New Data on APOE/TOMM40 Algorithm for Alzheimer's MCI Risk Premium The group demonstrated the ability of a genetic algorithm to gauge whether cognitively normal people are at risk of near-term mental decline. Researchers Use APOE-TOMM40 Haplotypes to Explain African-Americans' Unique Alzheimer's Risk Profile Premium NEW YORK (GenomeWeb) – Using a new in-phase assay, researchers led by Duke University's Allen Roses believe they have captured key differences in APOE and TOMM40 haplotypes between African-American, Caucasian, and West African populations. Takeda, Zinfandel Launch TOMMORROW Trial to Evaluate Alzheimer's Onset Risk Algorithm, AD-4833 Premium This article has been updated from a previous version to correct the pioglitazone dose to be used in the TOMMORROW trial. It is 0.8 mg/day, not 0.6 mg/day. Originally published Sept. 3. Takeda, Zinfandel Evaluate Genetic Risk Algorithm Ahead of Alzheimer's Delay Study with Diabetes Rx Premium Originally published July 23. Jun 19, 2013 Innovation Boom or Bust? Industry Gauges Impact of SCOTUS Ruling on Gene Patents Premium Jul 25, 2012 Rodent Study Suggests Low-Dose Pioglitazone May Improve Cognitive Function in Alzheimer's Patients Premium Jan 12, 2011 Takeda to Use Zinfandel's TOMM40 Test in Alzheimer's Development Program for Actos Premium Jan 11, 2011 Takeda to Use Zinfandel TOMM40 Biomarker Assay for Alzheimer's Drug Study Jul 14, 2010 Brain Imaging, Cognitive Evaluation Link TOMM40 Alterations to Alzheimer's Risk in Healthy Patients Premium Jan 6, 2010 Researchers Publish Data on Gene Variant Associated with Late-Onset Alzheimer's Disease Premium Breaking News People in the News at Probius, Flagship Biosciences, Discovery Life Sciences, More New Products Posted to GenomeWeb: BillionToOne, Becton Dickinson, Enzo Biochem, More Stroke Risk Contributors, Treatment Targets Uncovered in Cross-Ancestry GWAS In Brief This Week: Yourgene Health, Bionano Laboratories, Caris Life Sciences, More Enzymatic RNA Synthesis Firm EnPlusOne Biosciences Launches With $12M in Seed Funding The Scan Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says. Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds. Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry. UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.